Back to mobile site

Citi Would Buy Amarin (AMRN) Over The Medicines Company (MDCO)

November 20, 2019 6:56 AM EST Send to a Friend
Citi analyst Joel Beatty reiterated a Neutral rating and $59.00 price target on The Medicines Company (NASDAQ: MDCO) making the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login